Evidence map›Paper›PMID 39330191›Full record

ReviewGels (Basel, Switzerland)2024

Exploring Hydrogel Nanoparticle Systems for Enhanced Ocular Drug Delivery.

Zohreh Arabpour, Majid Salehi, Seungwon An, Amirhossein Moghtader, Khandaker N Anwar, Seyed Mahbod Baharnoori, Rohan Jaimin Shah, Farshad Abedi, Ali R Djalilian

Abstract readReview
In one paragraph

Review in Gels (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zohreh ArabpourDepartment of Ophthalmology and Visual Science, University of Illinois, Chicago, IL 60612, USA.ORCID 0009-0004-0996-4014
Majid SalehiDepartment of Tissue Engineering, School of Medicine, Shahroud University of Medical Sciences, Shahroud 3614773955, Iran.ORCID 0000-0001-6283-8181
Seungwon AnClinical Stem Cell Laboratory, UI Blood & Marrow Transplant Program, University of Illinois Hospital and Health Sciences System, Chicago, IL 60612, USA.
Amirhossein MoghtaderDepartment of Ophthalmology and Visual Science, University of Illinois, Chicago, IL 60612, USA.ORCID 0009-0005-3895-0655
Khandaker N AnwarDepartment of Ophthalmology and Visual Science, University of Illinois, Chicago, IL 60612, USA.ORCID 0000-0002-3846-8755
Seyed Mahbod BaharnooriDepartment of Ophthalmology and Visual Science, University of Illinois, Chicago, IL 60612, USA.ORCID 0000-0003-0919-1539
Rohan Jaimin ShahDepartment of Ophthalmology and Visual Science, University of Illinois, Chicago, IL 60612, USA.ORCID 0009-0000-6147-3555
Farshad AbediDepartment of Ophthalmology and Visual Science, University of Illinois, Chicago, IL 60612, USA.
Ali R DjalilianDepartment of Ophthalmology and Visual Science, University of Illinois, Chicago, IL 60612, USA.

Funding

Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHUKLA, DEEPAK · 1985 to 2025
$14.8M
Cell-derived therapies for corneal nerve repair: Structural and functional mechanismsR01EY035681 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALI R DJALILIAN, Mark I Rosenblatt · 2024 to 2026
$2.1M
Phase I Study of Mesenchymal Stromal Cell Secretome for Promoting Corneal RegenerationUH3EY031809 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALI R DJALILIAN · 2021 to 2026
$1.6M
Department of Defense VR170180NEI/NIH EY01792NEI NIH HHS P30 EY001792NEI NIH HHS R01 EY035681NEI NIH HHS UH3 EY031809R01 EY024349 (A.R.D.)UH3 EY031809 (A.R.D.)
6 · The paper itself

Abstract

Drug delivery to the ocular system is affected by anatomical factors like the corneal epithelium, blinking reflex, aqueous blood barrier, and retinal blood barrier, which lead to quick removal from the site and inefficient drug delivery. Developing a drug delivery mechanism that targets specific eye tissue is a major hurdle for researchers. Our study examines the challenges of drug absorption in these pathways. Hydrogels have been researched as a suitable delivery method to overcome some obstacles. These are developed alone or in conjunction with other technologies, such as nanoparticles. Many polymer hydrogel nanoparticle systems utilizing both natural and synthetic polymers have been created and investigated; each has pros and cons. The complex release mechanism of encapsulated agents from hydrogel nanoparticles depends on three key factors: hydrogel matrix swelling, drug-matrix chemical interactions, and drug diffusion. This mechanism exists regardless of the type of polymer. This study provides an overview of the classification of hydrogels, release mechanisms, and the role of controlled release systems in pharmaceutical applications. Additionally, it highlights the integration of nanotechnology in ocular disease therapy, focusing on different types of nanoparticles, including nanosuspensions, nanoemulsions, and pharmaceutical nanoparticles. Finally, the review discusses current commercial formulations for ocular drug delivery and recent advancements in non-invasive techniques. The objective is to present a comprehensive overview of the possibilities for enhancing ocular medication delivery through hydrogel nanoparticle systems.

Indexed as

hydrogelnanomedicinenanoparticleocular drug delivery

Identifiers

PMID39330191
PMCPMC11430953

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.